IL6 and neoplasm: Interestingly, ferritin, but not CRP and IL-6, was significantly (P <.05) but modestly (Spearman r < -0.3) associated with lower CAR T-cell expansion normalized to baseline tumor burden at days 7, 14, and 21 post infusion (Figures 1, S4).